Loading...

Table of Content

    25 April 2025, Volume 24 Issue 02 Previous Issue   
    For Selected: Toggle Thumbnails
    Advances in application of photon-counting CT for pancreatic imaging
    HUANG Ruikun, YANG Yanzhao, CHAI Weimin
    2025, 24 (02):  111-117.  DOI: 10.16150/j.1671-2870.2025.02.001
    Abstract ( 10 )   HTML ( 2 )   PDF (868KB) ( 0 )  

    Photon-counting computed tomography (PCCT) is an advanced CT imaging technology based on novel photon-counting detectors. Compared to traditional energy-integrating detector CT (EID-CT), PCCT demonstrates significant advantages in radiation dose utilization efficiency, image spatial resolution, and spectral resolution, and is expected to revolutionize imaging diagnostic paradigms for pancreatic diseases. This study systematically reviews the latest research advances in PCCT for pancreatic imaging, with a focus on its clinical application value in displaying fine pancreatic anatomical structures, visualizing the pancreas, surrounding vascular networks, and pancreaticobiliary systems, evaluating benign and malignant lesions, and quantitatively assessing tumor heterogeneity. The core technical principles of PCCT include physical characteristics such as high photon-flux processing by photon-counting detectors, K-edge imaging, and multi-energy threshold data acquisition modes. On this basis, this study summarizes optimization strategies for pancreatic imaging, including scan parameter settings and the clinical application of multimodal post-processing techniques. PCCT can effectively reduce radiation dose while overcoming the spatial resolution bottleneck, thereby improving the detection rate of cystic lesions. The low-energy monoenergetic reconstruction mode of PCCT can enhance the contrast of solid tumors and optimize the visualization of branching and tumor-feeding vessels. By integrating representative clinical studies and preliminary validation trials in recent years, this study further analyzes key challenges and corresponding strategies during the clinical translation of PCCT. Additionally, it explores the future directions of this technology in the precise diagnosis of pancreatic diseases, personalized treatment decision support, and the development of AI-big data models, aiming to provide a theoretical foundation and practical reference for promoting PCCT applications in the field of pancreatic imaging.

    References | Related Articles | Metrics
    Photon-counting CT in liver disease: applications and advances
    LI Weixia, YAN Fuhua
    2025, 24 (02):  118-124.  DOI: 10.16150/j.1671-2870.2025.02.002
    Abstract ( 7 )   HTML ( 0 )   PDF (543KB) ( 0 )  

    Photon-counting computed tomography (PCCT) represents a significant technological breakthrough in the field of CT imaging in recent years. This innovative technology utilizes novel semiconductor detectors to directly detect and count individual X-ray photons, enabling high-precision multi-energy data acquisition. Compared with traditional energy-integrating detector CT (EID-CT), PCCT offers significant technical advantages, including ultra-high spatial resolution (with a minimum detector pixel size of 0.15×0.18 mm), improved contrast-to-noise ratio (CNR increase of 15%-45%), and substantial radiation dose reduction (20%-90%). Moreover, PCCT can generate standardized CT value images, ensu-ring stable and reproducible quantitative measurements suitable for tissue composition analysis. With its ability to acquire data across multiple energy bins, PCCT achieves true multi-energy spectral imaging. In liver diseases, PCCT enables non-enhanced quantification of hepatic fat and iron content, with 70 keV standardized CT values showing a strong correlation with MRI-derived proton density fat fraction (PDFF). During contrast-enhanced scans, PCCT significantly improves the detection rate and lesion margin delineation of hypovascular tumors and allows accurate enhancement quantification through iodine maps. Additionally, PCCT enables ultra-low-dose, one-stop imaging that simultaneously provides functional hemodynamic parameters of hepatic microcirculation and high-quality multiphasic monoenergetic CT images for clinical diagnosis and preoperative planning—without the need for additional contrast medium or supplementary triphasic scans. This dual benefit of low radiation and contrast dose supports its clinical utility in liver imaging. This review focuses on recent advances in the application of PCCT in the diagnosis and treatment of diffuse and neoplastic liver diseases, aiming to provide theoretical foundations and practical insights for its broader implementation in precision hepatology.

    Figures and Tables | References | Related Articles | Metrics
    Application of photon-counting CT in cardiovascular diseases
    WANG Mengzhen, BAO Shouyu, LIU Peng, YAN Fuhua, YANG Wenjie
    2025, 24 (02):  125-134.  DOI: 10.16150/j.1671-2870.2025.02.003
    Abstract ( 10 )   HTML ( 1 )   PDF (983KB) ( 0 )  

    Photon-counting computed tomography (PCCT) is a revolutionary technological breakthrough in CT imaging over the past decade. Compared with traditional energy-integrating detector CT, PCCT performs imaging at the single-photon level at the detector layer, offering higher spatial resolution, fewer artifacts, and more accurate spectral imaging. PCCT shows great application potential in the diagnosis of cardiovascular diseases, especially in reducing beam-hardening artifacts and achieving ultra-high spatial resolution, which can further improve the specifi-city and positive predictive value in the assessment of coronary artery stenosis. This also contributes to the accurate evaluation of in-stent restenosis, reliable identification of plaque components, and characterization of vulnerable plaques. PCCT can obtain stable calcium scoring at low radiation doses. The virtual non-contrast (VNC) algorithm supports reliable calcium scoring from contrast-enhanced images, further reducing the radiation dose. PCCT can improve the reproducibility of features in pericoronary fat radiomics analysis. The VNC algorithm can accurately assess epicardial fat volume and significantly reduce radiation dose. Spectral images acquired by PCCT at high temporal resolution enable single-phase measurement of myocardial extracellular volume. They can also provide multidimensional anatomical information and functional parameters for preoperative planning and postoperative follow-up of transcatheter aortic valve implantation/replacement (TAVI/TAVR). Although PCCT holds great potential in the diagnosis of coronary artery disease and quantitative analysis of myocardial tissues, its quantitative results remain affected by reconstruction parameters such as convolution kernels, virtual monoenergetic levels, and iterative strength. Currently, a lack of unified standards and validation from multicenter studies, along with the increased radiation dose in ultra-high-resolution modes, still limits its wide clinical application. Future studies should focus on large-sample, multicenter prospective studies to optimize imaging parameters, standardize post-processing workflows, and integrate artificial intelligence tools to enhance the clinical application of PCCT in cardiovascular disease diagnosis.

    Figures and Tables | References | Related Articles | Metrics
    Analysis and interpretation of the 2022 Global Cancer Statistics Report: cancer burden and epidemiological trends in China and the world
    WU Qi, FAN Bonan, LI Yan
    2025, 24 (02):  135-145.  DOI: 10.16150/j.1671-2870.2025.02.004
    Abstract ( 27 )   HTML ( 1 )   PDF (1175KB) ( 9 )  

    In February 2024, the International Agency for Research on Cancer (IARC) released the 2022 Global Cancer Statistics Report. In 2022, there were nearly 20 million new cancer cases and 9.7 million deaths. The report provides statistics on the incidence and mortality of 36 different types of cancer in 185 countries around the world, analyzing geographic, gender-based, and Human Development Index (HDI)-related differences. It also predicts the global burden of cancer disease by 2050. Demographic forecasts suggest that by 2050, the number of new cancer cases worldwide is expected to reach 35 million annually-an increase of 77% compared to 2022. Geographically, cancer incidence and mortality rates show significant regional disparities. In 2022, nearly half (49.2%) of the world's new cases and the majority (56.1%) of cancer deaths occurred in Asia. In terms of gender distribution, the overall cancer incidence and mortality rate among females were lower than those among males in 2022. With respect to HDI, the risk of developing cancer increases with higher HDI levels. In 2022, the top 5 newly diagnosed cancer cases worldwide are lung cancer, female breast cancer cancer, colorectal cancer, prostate cancer, gastric cancer in turn. There were nearly 2.5 million new lung cancer cases and over 1.8 million related deaths. Breast cancer in women accounted for 2.3 million new cases and nearly 670 000 deaths. Colorectal cancer, including anal cancer, had more than 1.9 million new cases and over 900 000 deaths. Prostate cancer recorded 1.5 million new cases and nearly 400 000 deaths. There were nearly 970 000 newly-diagnosed cases of gastric cancer and 660 000 related deaths. In China in 2022, lung cancer still ranks first in the cancer incidence spectrum in China, accounting for 22.0% of the total new cases of cancer in China. This proportion has further increased compared to 2018 data (17.9%), followed by colorectal cancer (10.7%), thyroid cancer (9.7%), liver cancer (7.6%), and gastric cancer (7.4%), which account for more than half of the total new cases in China (57.4%). This paper reviews the data sources and statistical methods used in the report, interprets the epidemiological trends of major cancer types, and analyzes the incidence and burden of major cancers prevalent in China, provi-ding an overview of their disease burden and epidemiological trends.

    Figures and Tables | References | Related Articles | Metrics
    Study on consistency between liver fat fraction quantification based on photon-counting CT and MRI proton density fat fraction
    CAI Xinxin, DENG Rong, XU Xinxin, XU Zhihan, CHANG Rui, DONG Haipeng, LIN Huimin, YAN Fuhua
    2025, 24 (02):  146-154.  DOI: 10.16150/j.1671-2870.2025.02.005
    Abstract ( 8 )   HTML ( 0 )   PDF (1348KB) ( 0 )  

    Objective To investigate the consistency between CT-derived fat fraction (CT-FF) based on photon-counting CT material decomposition under different scanning conditions and magnetic resonance imaging proton density fat fraction (MRI-PDFF), thereby developing a CT-based method for liver fat quantification suitable for the Chinese population. Methods From September 2023 to February 2024, a total of 383 healthy volunteers were prospectively recruited at Ruijin Hospital, Shanghai Jiao Tong University School of Medicine (176 with PDFF < 5% and 207 with PDFF≥5%), and randomly assigned to four photon-counting CT scanning groups based on tube voltage (120 kVp/140 kVp) and radiation dose (standard dose/low dose). All subjects underwent photon-counting CT liver scanning and MRI examinations, with liver PDFF used as the reference standard for liver fat quantification. From the standard-dose group (n = 243), this study randomly selected 50 individuals each from the 120 kVp group (n = 123) and 140 kVp group (n = 120) to form a test cohort (n = 100), and the remaining subjects were assigned to the validation cohort (n = 283). Among volunteers with PDFF < 5% (n = 66) in the test cohort, this study randomly selected 20 individuals each from the 120 kVp group (n = 33) and 140 kVp group (n = 33) to form a threshold adjustment cohort (n = 40). The average CT values of liver and subcutaneous abdominal fat tissues were measured under low and high energy bins to serve as the thresholds for material decomposition. In the test cohort, the correlation and consistency between CT-FF and PDFF values obtained using thresholds before and after adjustment were compared. The performance of the adjusted threshold in measuring liver fat content was evaluated in the validation cohort, as well as the consistency across subgroups with different scanning protocols. Results BBased on data from the threshold adjustment cohort, the average CT values of liver tissue at 120 kVp and 140 kVp were 65 HU and 70 HU in the low and high energy bins, respectively. For fat tissue, the average CT values in the low and high energy bins were -127 HU and -96 HU at 120 kVp, and -125 HU and -92 HU at 140 kVp, which were used as the density thresholds for material decomposition. In the test cohort, after threshold adjustment, the correlation (r, 0.98 vs. 0.77), consistency (ICC, 0.980 vs. 0.770; r², 0.96 vs. 0.60), and mean difference (-0.7% vs. -18.1%) between CT-FF and PDFF values were significantly improved. In the entire validation cohort and across subgroups with different tube voltages and radiation doses, CT-FF and PDFF showed excellent correlation and consistency (r = 0.99, P < 0.001, r² = 0.98, ICC = 0.99), with mean differences not exceeding -0.7%. Conclusion Based on the liver tissue characteristics of the Chinese population, this study optimizes the density thresholds of the photon-counting CT material decomposition algorithm, and develops a fat quantification correction standard applicable to Chinese individuals for the first time, significantly improving measurement accuracy. This method may provide a new non-invasive and precise approach for liver fat quantification.

    Figures and Tables | References | Related Articles | Metrics
    Evaluation value of single-phase images from photon-counting CT-based low-dose pancreatic dynamic volume perfusion scanning for pancreatic cancer imaging
    CHANG Rui, LI Jiqiang, YANG Yanzhao, CHAI Weimin, YAN Fuhua, DONG Haipeng.
    2025, 24 (02):  155-162.  DOI: 10.16150/j.1671-2870.2025.02.006
    Abstract ( 8 )   HTML ( 1 )   PDF (2231KB) ( 0 )  

    Objective This study aims to evaluate the image quality of single-phase images in low-dose pancreatic dynamic volume perfusion computed tomography (VPCT) scans based on photon-counting computed tomography (PCCT) and assess their feasibility for morphological evaluation of pancreatic ductal adenocarcinoma (PDAC). Methods From April to August 2024, participants suspected of PDAC were prospectively enrolled and underwent preoperative pancreatic VPCT scans. A total of 55 patients with pathologically confirmed PDAC were included, and radiation doses were recorded and calculated. Perfusion time-attenuation curves were analyzed, and optimal single-phase images of pancreatic parenchymal phase and portal venous phase were extracted from T3D, 55 keV, and 70 keV virtual monoenergetic images (VMIs) for clinical diagnosis and morphological evaluation of PDAC. Subjective scoring of images was performed, and CT values of lesions, normal pancreatic parenchyma, peripancreatic vessels, and abdominal wall fat were measured. The standard deviation of the CT value of abdominal wall fat was used as the image noise value. Signal-to-noise ratios (SNRs) of lesions, normal pancreatic parenchyma, and peripancreatic vessels, as well as contrast-to-noise ratios (CNRs) of lesions and peripancreatic vessels were calculated. Inter-observer agreement of subjective evaluations was evaluated using Cohen's kappa coefficient. One-way repeated measures ANOVA and Friedman H tests were used to compare the quantitative evaluation indicators and subjective scores among groups. Results The VPCT scanning achieved an average effective radiation dose of (18.0±4.9) mSv. The single-phase images of pancreatic parenchymal phase and portal venous phase extracted from reconstructed images met clinical diagnostic quality standards, with all subjective image quality scores above 3 points. In the single-phase images of pancreatic parenchymal phase reconstructed at 55 keV VMI, the CNR of PDAC lesions was 11.1±4.4, while for T3D it was 9.1±3.7 and for 70 keV VMI it was 8.0±3.2. In images of portal venous phase reconstructed at 55 keV VMI, the CNR of PDAC lesions was 6.3±3.0, while for T3D it was 5.7±3.0 and for 70 keV VMI, it was 4.9±2.7. Single-phase images reconstructed from 55 keV VMI showed the highest CNR of PDAC lesions (P<0.001), along with the highest SNR of normal pancreatic parenchyma and peripancreatic vessels, the highest CNR of peripancreatic vessels, and optimal subjective contrast scores of PDAC lesions. There was no significant difference in image noise between 55 keV VMI and T3D reconstructed single-phase images [parenchymal phase: (8.3±2.1) vs. (8.2±2.1), portal venous phase: (8.4±2.1) vs. (8.3±2.2)] (P=0.599, 0.683). Both had higher image noise than that of 70 keV VMI (parenchymal phase: 7.1±1.9, portal venous phase: 7.3±1.8) (P<0.001). Conclusion Single-phase images obtained from perfusion scanning PCCT-based low-dose pancreatic dynamic VPCT imaging protocols can be used for PDAC imaging and morphological evaluation. The 55 keV VMI reconstruction can further optimize the image quality of PDAC.

    Figures and Tables | References | Related Articles | Metrics
    Prospective study on quantitative evaluation of femoral neck bone mineral density using spectral localizer radiograph from photon-counting detector CT
    ZHOU Shanshui, QIN Le, CHANG Rui, DU Lianjun, YAN Fuhua, LIU Fangtao
    2025, 24 (02):  163-169.  DOI: 10.16150/j.1671-2870.2025.02.007
    Abstract ( 9 )   HTML ( 0 )   PDF (2276KB) ( 0 )  

    Objective To evaluate the performance of spectral localizer radiograph (SLR) acquired by photon-counting detector CT (PCD-CT) for the quantitative assessment of areal bone mineral density (aBMD) in the femoral neck. Methods From July 2024 to April 2025, subjects (≥18 years old) scheduled for both dual-energy X-ray absorptiometry (DXA) and CT scans were prospectively enrolled. All subjects underwent PCD-CT examinations to obtain SLR, and two observers independently performed blinded measurements of the aBMD in the left femoral neck on the SLR. The measurement results of DXA were used as the reference standard to evaluate the quantitative accuracy of SLR for aBMD and its diagnostic performance for abnormal bone mass (T-score<-1.0). Results A total of 63 subjects (36 females) were enrolled, with a mean age of 64.30±13.20 years. The median aBMD measured by DXA was 0.889 [interquartile range (IQR), 0.749-1.031] g/cm2, and 23 subjects (36.51%) showed abnormal bone mass. The aBMD values measured by the two observers were 0.879 (0.760-0.985) g/cm2 and 0.891 (0.784-0.977) g/cm2, respectively. SLR-based measurements of aBMD demonstrated excellent inter-observer agreement (intraclass correlation coefficient = 0.98). Using DXA results as the reference, the median absolute percentage error of aBMD measured by SLR was 6.66% (IQR, 3.64%-9.80%). The diagnostic accuracy, sensitivity, and specificity of SLR for diagnosing abnormal bone mass were 95.24% (50/63), 95.65% (22/23), and 95.00% (38/40), respectively. Conclusions Spectral localizer radiographs acquired by PCD-CT can accurately quantify bone mineral density in the femoral neck and demonstrate high diagnostic performance for abnormal bone mass.

    Figures and Tables | References | Related Articles | Metrics
    Value of synthetic MRI in predicting treatment response to neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer
    WANG Kangning, ZHU Lan, FENG Weiming, XIA Yihan, SHI Bowen, ZHANG Huan
    2025, 24 (02):  170-177.  DOI: 10.16150/j.1671-2870.2025.02.008
    Abstract ( 10 )   HTML ( 1 )   PDF (834KB) ( 0 )  

    Objective To explore the effectiveness of synthetic MRI sequences in predicting the treatment response of patients with locally advanced rectal cancer (LARC) undergoing neoadjuvant chemoradiotherapy treatment (nCRT). Methods A total of 51 patients with biopsy-confirmed rectal adenocarcinoma were enrolled at Ruijin Hospital from August 2023 to June 2024. All patients were assessed as having LARC by baseline MRI and received nCRT followed by radical surgery. All subjects completed synthetic MRI and high-resolution T2-weighted imaging (T2WI) scans within two weeks before receiving nCRT treatment. Based on high-resolution T2WI images, radiologists assessed extramural vascular invasion (mrEMVI) at baseline in the subjects. After the synthetic MRI sequence scanning was completed, synthetic images of T1 mapping, T2 mapping, and proton density (PD) mapping were generated using Synthetic MR post-processing software. Histogram-based quantitative parameters at baseline were extracted using python software, including quantitative parame-ters of the primary tumor and peritumoral fat region: T1 relaxation time (T1RT), T2 relaxation time (T2RT), and proton density (PD). Using postoperative pathological results as the gold standard, patients were grouped according to: (1) primary tumor response: pathological complete response (pCR) vs. non-pCR; (2) tumor regression grade: (TRG) 0-1 vs. TRG 2-3; and (3) mesorectal lymph node metastasis status: positive (ypN+) vs. negative (ypN-). Differences in baseline mrEMVI status and quantitative parameters of the primary tumor and peritumoral fat among different groups were compared using Student's t-test, Mann-Whitney U test, and Chi-square test. Binary logistic regression was used to identify independent risk factors for predicting TRG grade, pCR status, and mesorectal lymph node status. Based on the selected risk factors, logistic regression models were established. The predictive performance of the quantitative parameters, mrEMVI status, and the regression models for TRG grade, pCR status, and mesorectal lymph node status was evaluated using receiver operating characteristic (ROC) curves. Results Baseline mrEMVI positivity (P=0.03) and quantitative parameters of peritumoral fat tissue-including the maximum T2RT_Fat (139.53 ms vs. 129.60 ms, P=0.03), 90th percentile (189.18 ms vs. 174.00 ms, P=0.03), root mean square (120.09 ms vs. 115.48 ms, P=0.04), and lower T2RT_Fat uniformity (0.54 vs. 0.61, P=0.04)—were indicative of positive mesorectal lymph node status after nCRT. None of the observed indicators were correlated with the primary tumor response. Logistic regression analysis showed that mrEMVI and elevated T2RT_Fat_P90 were independent risk factors for predicting mesorectal lymph node metastasis. The logistic regression model combining both mrEMVI (AUC=0.667) and T2RT_Fat_P90 (AUC=0.692) demonstrated good predictive performance (AUC=0.747), although the improvement was not statistically significant. Conclusions T2RT_Fat_P90, extracted from baseline MAGiC synthetic MRI serves as a non-invasive imaging biomarker for predicting mesorectal lymph node metastasis after nCRT. The combination of T2RT_Fat_P90 and baseline mrEMVI can be used as an auxiliary tool for predicting the mesorectal lymph node metastasis status in LARC patients following nCRT.

    Figures and Tables | References | Related Articles | Metrics
    Distribution of BRAFV600E mutation in cytological samples of thyroid nodules and its clinical application value
    WANG Lei, JIN Jingjing, YU Na, XIAO Li
    2025, 24 (02):  187-193.  DOI: 10.16150/j.1671-2870.2025.02.010
    Abstract ( 10 )   HTML ( 0 )   PDF (999KB) ( 0 )  

    Objective To investigate the distribution characteristics of BRAFV600E mutation in cytological diagnosis of thyroid fine-needle aspiration cytology (FNAC) and analyze the diagnostic value of combining FNAC with BRAFV600E mutation detection for the preoperative diagnosis of papillary thyroid carcinoma (PTC). Methods A retrospective analysis was conducted on 261 consecutive thyroid nodules that underwent FNAC at Huadong Hospital Affiliated to Fudan University between November 2021 and January 2024. All nodules were tested for mutations in BRAF, TERT, RET, HRAS, KRAS, NRAS, PPARG, and NTRK genes using the amplification refractory mutation system-polymerase chain reaction (ARMS-PCR). The distribution of BRAFV600E mutations across the Bethesda system for reporting thyroid cytopathology (TBSRTC) was analyzed. Among the 261 thyroid nodules, 69 underwent postoperative histopathological examination, including 65 diagnosed as PTC, 3 as follicular tumors, and 1 as a follicular nodule. Using postoperative histopathology as the gold standard, the diagnostic value (accuracy, sensitivity, and specificity) of FNAC combined with BRAFV600E mutation detection for preoperative PTC diagnosis was analyzed. Results Among the 261 FNAC samples, 98 thyroid nodules were BRAFV600E -positive, with 78.6% of positive samples classified as category Ⅴ or Ⅵ in the TBSRTC. The accuracy of FNAC, BRAFV600E mutation detection, and their combination in differentiating PTC was 76.8%, 81.2%, and 89.9%, respectively. The sensitivi-ty was 76.9%, 80.0%, and 90.8%, and the specificity was 75.0%, 100.0%, and 75.0%, respectively. The area under the ROC curve (AUC) for each method was 0.759 6, 0.900 0, and 0.828 8, respectively. Z-test results showed that the AUC of FNAC combined with BRAFV600E mutation detection was improved compared to that of FNAC alone (P=0.008 2). Conclusion This study has found that 78.6% of BRAFV600E mutation-positive cases were classified as categories Ⅴ and Ⅵ in the TBSRTC, indicating that BRAFV600E mutation detection can serve as an important supplementary marker for diagno-sing high-risk PTC nodules. Compared with FNAC alone, the combination of FNAC and BRAFV600E mutation detection improves the preoperative diagnostic accuracy of PTC.

    Figures and Tables | References | Related Articles | Metrics
    Ultrasound viscoelastic imaging in differentiation of benign and malignant breast tumors
    QIN Yu, LI Cheng, HUA Qing, ZHANG Huiting, JIA Wanru, DONG Yijie, ZHOU Jianqiao, XIA Shujun
    2025, 24 (02):  194-203.  DOI: 10.16150/j.1671-2870.2025.02.011
    Abstract ( 16 )   HTML ( 1 )   PDF (1242KB) ( 4 )  

    Objective To evaluate the application value of ultrasonic viscoelastic imaging technology in differentia-ting benign and malignant breast tumors. Methods A total of 717 patients with breast tumors confirmed by surgical patho-logy were consecutively enrolled at Ruijin Hospital, Shanghai Jiao Tong University School of Medicine between February 2023 and August 2023, including 471 malignant and 246 benign cases. All patients underwent breast ultrasound examinations before treatment, including grayscale ultrasound, ultrasound strain elastography, ultrasound shear wave elastography, and ultrasound viscoelastic imaging. Ultrasound viscoelastic imaging technology included measuring four sets of parameters of the tumor and its surrounding tissues: viscosity coefficient, dispersion coefficient, shear wave elastic modulus, and strain ratio. Using the optimal predictive indicators from the four parameter groups, multiple prediction models were established, including single-variable models (viscosity coefficient, dispersion coefficient, shear wave, strain), a combined viscoelastic model (Shell/T-Vmean + Shell/T-Dmean), a Breast Imaging Reporting and Data System (BI-RADS) model, and a combined model integrating BI-RADS with viscoelastic parameters. The effectiveness of each model in differentiating benign and malignant breast tumors was evaluated. Results Parameters including viscosity coefficient, dispersion coefficient, elastic modulus, and strain ratio from ultrasound viscoelastic imaging could effectively distinguish benign and malignant breast tumors. Among them, the ratios of the tumor margin (2 mm region) to the tumor itself—Shell/T-Vmean, Shell/T-Dmean, Shell/T-Emean, and Strain Ratio A—were optimal predictive indicators, with areas under the curve (AUCs) of 0.742, 0.745, 0.726, and 0.705, respectively. The BI-RADS model for predicting benign and malignant breast tumors achieved an AUC of 0.822. When Shell/T-Vmean and Shell/T-Dmean were respectively combined with BI-RADS classification, the receiver operating characteristic (ROC) curve's AUC reached 0.895 (95% CI: 0.868–0.917), which was higher than that of BI-RADS alone. Conclusion Among the viscoelastic parameters of ultrasound viscoelastic imaging, the average ratios of viscosity coefficient, dispersion coefficient, and elastic modulus between the 2 mm tumor margin region and the tumor body are key diagnostic indicators. The combination of Shell/T-Vmean and Shell/T-Dmean with BI-RADS provides a new stra-tegy for noninvasive preoperative precision diagnosis.

    Figures and Tables | References | Related Articles | Metrics
    Value of miR-2355-3p,miR-337-3p and miR-99a-5p detection in early screening of head and neck squamous cell carcinoma
    LIU Jinghao, GUO Haiyan, GAN Guifang, CHEN Fuxiang
    2025, 24 (02):  204-211.  DOI: 10.16150/j.1671-2870.2025.02.012
    Abstract ( 8 )   HTML ( 0 )   PDF (591KB) ( 0 )  

    Objective To explore the value of miR-2355-3p, miR-337-3p, and miR-99a-5p in the early screening of head and neck squamous cell carcinoma (HNSCC). Methods Serum samples and clinicopathological data were collected from 60 newly diagnosed HNSCC patients (HNSCC group) and 60 healthy individuals (normal control group) who visited the Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine between July 2023 and July 2024. The relative expression levels of miR-2355-3p, miR-337-3p, and miR-99a-5p were determined using parallel detection. The HNSCC screening and diagnostic efficacy of these three miRNAs was evaluated using receiver operating characteristic (ROC) curves. Results Compared with the normal control group, serum levels of miR-2355-3p and miR-337-3p were significantly upregulated in the HNSCC group (P<0.001), while miR-99a-5p was significantly downregulated (P=0.002). The expression levels of miR-2355-3p and miR-337-3p differed significantly among HNSCC patients with tumor size >2 cm versus ≤2 cm, clinical stage Ⅰ–Ⅱ versus stage Ⅲ–Ⅳ, and with versus without cervical lymph node metastasis (P<0.05). However, no significant differences in miRNA expression were found across different age or gender groups (P>0.05). The optimal cutoff values for diagnosing HNSCC were 0.0867 for miR-2355-3p, 0.1031 for miR-337-3p, and 0.1251 for miR-99a-5p, with corresponding areas under the curve (AUCs) of 0.892, 0.877, and 0.686, respectively. The combined detection of the three miRNAs yielded an AUC of 0.954, significantly higher than those of individual markers (P<0.05) and the combination of miR-2355-3p and miR-337-3p (AUC=0.898, P<0.05). The AUC for the combined detection in early-stage (stage Ⅰ–Ⅱ) HNSCC was 0.923. Conclusions miR-2355-3p and miR-337-3p are associated with the tumor stage, size, and lymph node metastasis of HNSCC. The combined detection of miR-2355-3p, miR-337-3p, and miR-99a-5p may serve as a potential method for early screening of HNSCC.

    Figures and Tables | References | Related Articles | Metrics
    Clinical applications of photon-counting CT in neuroimaging
    LÜ Haiying, LU Yong, HE Naying
    2025, 24 (02):  212-219.  DOI: 10.16150/j.1671-2870.2025.02.013
    Abstract ( 8 )   HTML ( 2 )   PDF (1921KB) ( 0 )  

    Photon-counting computed tomography (PCCT) is a next-generation CT imaging technology that markedly improves image quality while reducing radiation dose and image noise through single-photon detection and energy discrimination by photon detectors. At present, PCCT holds broad clinical application prospects in the field of neuroimaging, especially demonstrating unique advantages in the visualization of fine intracranial structures, the diagnosis and treatment monitoring of intracranial aneurysms, and the diagnosis and treatment of intracranial artery stenosis and spinal vascular lesions. In ultra-high-resolution (UHR) mode (slice thickness of 0.2 mm), PCCT of the head and neck arteries achieves high signal-to-noise ratios using BV64-BV72 convolution kernel reconstruction. With the digital subtraction angiography (DSA) as the gold standard, UHR-PCCTA shows sensitivity, specificity, accuracy, and inter-rater agreement of approximately 98.0%, 96.7%, 97.3%, and 0.95 (Kappa values), respectively, in diagnosing small intracranial aneurysms. In addition, UHR-PCCT significantly outperforms conventional energy-integrating detector CT (EID-CT) in identifying aneurysm irregularity, aneurysm wall, and intraluminal features. UHR-PCCT is expected to enable precise evaluation of the degree of arterial stenosis, potentially approaching the accuracy of DSA. With its multi-energy virtual monoenergetic reconstructions, it shows promise for quantitative analysis of intracranial athe-rosclerotic plaques and prediction of plaque rupture risk. Under sharp reconstruction kernels (e.g., BV72-BV80), PCCT enables clear visualization of intracranial arterial stents and residual aneurysms, offering a new noninvasive alternative to DSA for postope-rative monitoring of intracranial artery treatments. The diversified applications of PCCT in neuroimaging will lay a foundation for its better role in the diagnosis and treatment of neurological diseases. However, the widespread application of PCCT in the neurological field remains limited by factors such as restricted equipment availability, the need for imaging optimization in specific scenarios (e.g., small perforating arteries, severe calcifications, or metallic implants), and the lack of support from large-scale clinical validation data. In the future, it is necessary to gradually overcome these limitations through continued hardware upgrades, algorithmic optimization, and the advancement of multicenter prospective studies to fully unleash the clinical potential of PCCT.

    Figures and Tables | References | Related Articles | Metrics
    Research progress on positron emission tomography using radionuclide-labeled fibroblast activation protein inhibitor in diagnosis of cardiac diseases
    JIA Yingqi, ZHANG Min, LI Biao
    2025, 24 (02):  220-225.  DOI: 10.16150/j.1671-2870.2025.02.014
    Abstract ( 8 )   HTML ( 0 )   PDF (505KB) ( 0 )  

    Fibroblast activation protein (FAP) is a type Ⅱ transmembrane serine protease specifically expressed on the surface of activated cardiac fibroblasts (CFs). During myocardial injury, inflammation, and fibrosis, it drives myocardial interstitial remodeling and collagen deposition by degrading the extracellular matrix and activating key pathways such as transforming growth factor-β (TGF-β), thus serving as a central effector target in the development of myocardial fibrosis. FAP is significantly upregulated exclusively in activated CFs, with minimal expression in normal myocardial tissue, provi-ding a molecular basis for the non-invasive and precise diagnosis of cardiac diseases. In recent years, radionuclide-labeled FAP inhibitor (FAPI) positron emission tomography (PET), with its non-invasiveness, high targeting specificity, and quantitative evaluation capability, has enabled the early detection of microfibrosis signals at the molecular level. This technique overcomes the reliance of conventional imaging (e.g., cardiac magnetic resonance) on structural changes, demonstrating unique advantages in the dynamic evaluation of active myocardial fibrosis and providing a novel pathway for early diagnosis, exploration of pathological mechanisms, and prognostic evaluation of cardiac diseases. Current research confirms that FAPI-PET holds significant application value across multiple cardiac diseases. For example, in left ventricular remodeling after acute myocardial infarction, dynamic monitoring of FAP activity in the peri-infarct zone can predict ventricular dilation and adverse remodeling trends. In cardiotoxicity induced by radiotherapy, chemotherapy, or immunotherapy, it achieves early warning of subclinical fibrosis. For cardiac amyloidosis, it facilitates early quantification of myocardial fibrotic burden and assists in risk stratification and prognosis evaluation across different subtypes. In pulmonary hypertension and right ventricular remodeling, it can comprehensively evaluate diffuse fibrosis and reflect the severity of the di-sease. For different subtypes of cardiomyopathy (e.g., hypertrophic/dilated), it assists in clinical phenotype identification by analyzing the spatial distribution of fibrosis. Additionally, it can be used to evaluate the atrial injury repair responses after catheter ablation for atrial fibrillation, thereby predicting the risk of arrhythmia recurrence. This study reviews domestic and international research advances in the application of FAPI-PET in the diagnosis of cardiac diseases, and discusses its application potential and future challenges.

    References | Related Articles | Metrics
    Research progress on clinical application of anti-tissue factor pathway inhibitor in hemophilia
    XIAO Jianwen, YI Weijia
    2025, 24 (02):  226-232.  DOI: 10.16150/j.1671-2870.2025.02.015
    Abstract ( 11 )   HTML ( 3 )   PDF (612KB) ( 0 )  

    In recent years, to address the unmet needs in hemophilia treatment, significant research has led to unprecedented advances in pharmacotherapy, including the development of several innovative mechanism-based therapies that restore hemostatic balance by modulating thrombin generation in hemophilia patients with or without inhibitors. Among them, non-factor therapies involving hemostatic rebalancing mechanisms have achieved remarkable progress, with one of the key focuses in clinical development being anti-tissue factor pathway inhibitor (TFPI) therapy. TFPI is a key anticoagulant protein in the coagulation pathway that inhibits tissue factor (TF)-mediated initiation of coagulation. Blocking TFPI activity can enhance thrombin generation, providing a novel approach for hemophilia treatment. Notably, this mechanism applies to patients with hemophilia A or B and is theoretically effective for patients with or without inhibitors. As of June 2025, anti-TFPI agents that have entered clinical development or been approved for marketing internationally include concizumab, marstacimab, befovacimab, KN057, and MG1113. These agents inhibit TFPI activity through different antibody types, employing varying binding affinities or targeting distinct domains of TFPI. Studies on clinical trials across various phases have demonstrated that these drugs have good efficacy in reducing annual bleeding rates and improving patient prognosis. In addition, anti-TFPI drugs are administered subcutaneously, with dosing intervals up to one week, providing convenience for patients. Anti-TFPI therapy represents an important shift in the field of hemophilia management. However, it faces some challenges, including potential thrombotic risks and the current absence of suitable laboratory assays to monitor treatment efficacy.

    Figures and Tables | References | Related Articles | Metrics
    X-linked agammaglobulinemia with bronchiectasis and infection: a case report
    LIN Jiayuan, CHENG Qijian, CHEN Ling
    2025, 24 (02):  233-237.  DOI: 10.16150/j.1671-2870.2025.02.016
    Abstract ( 6 )   HTML ( 1 )   PDF (762KB) ( 0 )  

    X-linked agammaglobulinemia (XLA) is a rare disease characterized by severe hypogammaglobulinemia, antibody deficiency, and recurrent infections. This study reports a case of X-linked agammaglobulinemia combined with bronchiectasis and infection. The patient was a 45-year-old male with a disease course of more than 40 years, mainly presenting with recurrent infections such as pneumonia, sinusitis, and otitis media. After the patient was admitted due to bronchiectasis with infection this time, laboratory tests showed that the levels of IgM, IgA, and IgG were 0.24 g/L, 0.90 g/L, and 4.33 g/L, respectively, all significantly decreased, and the peripheral blood CD19+B lymphocyte count was 0.1%. Genetic testing results showed that the patient had a c.1095C>A (p.Asn365Lys) mutation in the Bruton's tyrosine kinase (Btk) gene. This case suggests that male patients with a history of recurrent infections and imaging evidence of bronchiectasis should further understand their family history, improve humoral and cellular immune testing, and perform genetic testing in a timely manner, which is beneficial for the early diagnosis and treatment of XLA.

    Figures and Tables | References | Related Articles | Metrics
    Design and practice of ideological education in the “clinical laboratory transfusion medicine” based on blended teaching
    JIANG Xiaoxing, DAI Jianmin, CHEN Ning, CAI Xiaohong
    2025, 24 (02):  238-240.  DOI: 10.16150/j.1671-2870.2025.02.017
    Abstract ( 8 )   HTML ( 1 )   PDF (1140KB) ( 0 )  
    Figures and Tables | References | Related Articles | Metrics